Niox Group Plc

DUBLIN--( BUSINESS WIRE )--The "mHealth and Home Monitoring - 12th edition" report has been added to ResearchAndMarkets.com's offering. The number of connected home medical monitoring devices on the global market was 76.7 million at the end of 2023 and is forecasted to grow at a CAGR of 12.8 percent in the next five years to reach 140.1 million in 2028. The adoption of mHealth solutions in healthcare is driven by a wide range of incentives, related to everything from demographics and technology development to new advancements in medical treatment. The primary focus of this report is on home monitoring solutions, which are commonly used to manage patients with various chronic conditions such as cardiac arrhythmia, sleep apnoea and diabetes. Other applications include remote diagnostics, compliance monitoring and clinical trials. The revenues for remote patient monitoring (RPM) solutions reached 40.4 billion in 2023, including revenues from medical monitoring devices and mHealth software and services. RPM revenues are expected to grow at a CAGR of 13.9 percent between 2023 and 2028 to reach 77.3 billion at the end of the forecast period. Connected medical devices accounted for 54 percent of total RPM revenues in 2023. However, revenues for mHealth software and services are growing at a faster rate and will account for 58 percent of total revenues in 2028, up from 46 percent in 2023. This report will allow you to: Learn about key home health monitoring devices and services. Study the strategies of 145 key players in the mHealth ecosystem. Understand the dynamics of the health monitoring market in Europe and North America. Comprehend how wireless technology can become seamlessly integrated with medical devices. Evaluate the business opportunities in the emerging mHealth segment. Predict future market and technology developments. The report answers the following questions: Which medical conditions offer the best potential for wireless health monitoring solutions? Who are the leading providers of connected medical devices? What are the mHealth strategies of medical device vendors and pharmaceutical companies? What initiatives have been taken by the leading players in the telecom and IT industries? How can connectivity redefine the use cases of medical devices and the value to patients? Which are the general technology trends for home health monitoring equipment? How are new reimbursement policies affecting the mHealth and connected care market? How can healthcare providers and payers benefit from mHealth solutions? Key Attributes: Report Attribute Details No. of Pages 320 Forecast Period 2023 - 2028 Estimated Market Value (USD) in 2023 $76.7 Million Forecasted Market Value (USD) by 2028 $140.1 Million Compound Annual Growth Rate 12.8% Regions Covered Global Key Topics Covered: 1 The Challenge of Chronic Diseases 1.1 Introduction 1.1.1 The ageing population 1.1.2 Lifestyle-related diseases 1.2 Common chronic diseases 1.2.1 Cardiac arrhythmia 1.2.2 Chronic respiratory diseases 1.2.3 Congestive Heart Failure (CHF) 1.2.4 Diabetes 1.2.5 Hyperlipidaemia 1.2.6 Hypertension 1.2.7 Ischemic diseases 1.2.8 Sleep apnoea 1.3 Healthcare providers and reimbursement systems 1.4 Regulatory environment 2 mHealth Platforms 2.1 Overview of the mHealth market 2.1.1 mHealth market segments 2.1.2 Connectivity options for medical devices 2.1.3 The mHealth technology value chain 2.2 mHealth connectivity solutions Alphabet Apple Bittium Deutsche Telekom eDevice Enovacom (Orange) KORE MedM Microsoft PTC Telenor Vodafone 2.3 mHealth care delivery platforms AT&T Alira Health (Bepatient) Aptar Digital Health Clario Doccla (OpenTeleHealth) Domicalis Enovation (Legrand Care) Hope Care Huma Therapeutics Luscii (Omron Healthcare) Medisante Medixine S3 Connected Health Sony Network Communications TruBridge 3 Physiological Monitoring Solution Providers 3.1 Medical devices and remote monitoring 3.2 Cardiac rhythm management 3.2.1 Overview of the CRM device market 3.2.2 Use cases for CRM monitoring 3.2.3 Remote monitoring solution providers Abbott (St. Jude Medical) BIOTRONIK Boston Scientific Medtronic MicroPort Scientific 3.3 Remote ECG monitoring 3.3.1 Overview of the remote ECG monitoring device market 3.3.2 Use cases for remote ECG monitoring 3.3.3 Remote monitoring solution providers AliveCor Boston Scientific Cardiac Diagnostics (Preventice Solutions) BioTelemetry (Philips ECG Solutions) Biotricity CardioComm Solutions GE HealthCare InfoBionic.Ai iRhythm Technologies LevMed ScottCare Cardiovascular Solutions TZ Medical VitalConnect Vivalink Zenicor Medical Systems 3.4 Blood pressure monitoring 3.4.1 Overview of the blood pressure monitoring device market 3.4.2 Use cases for blood pressure monitoring 3.4.3 Remote monitoring solution providers 3.4.4 A&D Holon Holdings Company iHealth Labs Microlife Omron Healthcare Smart Meter Rossmax Welch-Allyn (Baxter International) Withings 3.5 Coagulation monitoring 3.5.1 Overview of the coagulation monitoring device market 3.5.2 Use cases for blood coagulation monitoring 3.5.3 Remote monitoring solution providers CoaguSense Helena Laboratories iLine Microsystems Roche Diagnostics Siemens Healthineers Werfen (Instrumentation Laboratory) 3.6 Sleep therapy monitoring 3.6.1 Overview of the sleep therapy device market 3.6.2 Use cases for sleep therapy monitoring 3.6.3 Remote monitoring solution providers BMC Medical Fisher & Paykel Healthcare Lowenstein Medical Technology Philips Sleep and Respiratory Care ResMed SRETT Somnics Health SomnoMed 3.7 Home sleep diagnostics 3.7.1 Overview of the home sleep diagnostics market 3.7.2 Use cases for home sleep diagnostics 3.7.3 Remote monitoring solution providers Acurable BioSerenity Cadwell Laboratories CleveMed Compumedics Natus Medical Nox Medical Onera Health SOMNOmedics Wesper Zoll Itamar 3.8 Blood oxygen monitoring 3.8.1 Overview of the blood oxygen monitoring device market 3.8.2 Use cases for blood oxygen monitoring 3.8.3 Remote monitoring solution providers BodiMetrics ChoiceMMed Masimo Nonin Medical 3.9 Airflow monitoring 3.9.1 Overview of the air flow monitoring device market 3.9.2 Use cases for airflow monitoring 3.9.3 Remote monitoring solution providers AstraZeneca Adherium Medical International Research Monitored Therapeutics NDD Medical Technologies NIOX Group (Circassia Group) Propeller Health Respiri Sibelmed Smart Respiratory Vitalograph 3.10 Glucose level monitoring 3.10.1 Overview of the glucose monitoring device market 3.10.2 Use cases for glucose monitoring 3.10.3 Remote monitoring solution providers Abbott Diabetes Care Ascensia Diabetes Care BioTel Care (Philips) Dexcom Glooko Insulet LifeScan Medtronic Diabetes Operating Unit Roche Diabetes Care Senseonics Tandem Diabetes Care Welldoc 3.11 Other 3.11.1 Implantable medical devices 3.11.2 Home haemodialysis 3.11.3 Thermometers and weight scales 3.11.4 Mental health 3.11.5 Cholesterol monitoring 4 Medication, AED and Integrated Monitoring Solution Providers 4.1 Telehealth and multiparameter monitoring solutions 4.1.1 Overview of the telehealth solutions market 4.1.2 Use cases for telehealth solutions 4.1.3 Telehealth solution providers Accuhealth AMC Health American Well (Amwell) Biofourmis CareSimple Current Health (BestBuy Health) Medtronic Care Management Services Philips Enterprise Telehealth SHL Telemedicine Teladoc Health Telefonica TytoCare 4.2 Medication compliance monitoring 4.2.1 Overview of the medication compliance monitoring market 4.2.2 Use cases for medication compliance monitoring 4.2.3 Compliance monitoring solution providers AceAge AdhereTech Compliance Meds Technologies etectRx Evondos Hero Information Mediary Corporation iZafe Group Medimi MedMinder MedReady Merck Group Mevia RGF Diagnostics (Mymemo) Spencer Health Solutions Vaica 4.3 Connected automated external defibrillators 4.3.1 Overview of the connected defibrillator market 4.3.2 Use cases for automated external defibrillators 4.3.3 Connected solution providers Almas Industries Avive Solutions Cardia International CardiLink Metrax Nihon Kohden Philips Emergency Care Physio-Control (Stryker) PYRESCOM Schiller Zoll Medical (Asahi Kasei) 5 Market Analysis and Forecasts 5.1 Market forecasts 5.2 Revenue forecasts 5.3 Market drivers and barriers An ageing population increases the demand for care services Increase of non-communicable disease prevalence The generational technology barrier is disappearing Healthcare staff shortages calls for more efficient healthcare Increasing government reimbursement for mHealth applications Transformation to value-based care Increased focus on disease prevention Substitutes to medical monitoring A slowly changing industry Critical role of cybersecurity in digital solutions Increased need for interoperability as the number of solutions grows 5.4 Industry trends and analysis The role of AI and machine learning in transforming mHealth Integrations are becoming crucial in the health data ecosystem Consumerization of medical-grade mHealth devices and apps How cellular technologies enable reliable connectivity for medical devices Major pharmaceutical companies prepare large-scale rollouts BYOD is becoming a popular and viable option The global adoption of telehealth is ramping up Compliance monitoring is a major driver behind home monitoring COVID-19 became a catalyst that took mHealth into the next growth phase For more information about this report visit https://www.researchandmarkets.com/r/hyqq5r About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

“At Santander Pharma Consulting, our mission is clear: to help our clients optimize their commercial success by leveraging our teams’ experience,” said Robert Yanez, the firm's co-founder and CEO. There’s a new life-sciences-focused consulting firm in town. Founded by a duo with about half a century’s worth of experience in biopharma and medtech between them, Santander Pharma Consulting—no relation to the major banking firm—stepped into the spotlight with a launch announcement Tuesday. The firm, based in Durham, North Carolina, will offer a range of support services to drug and devicemakers of all sizes, though its focus is on “small or emerging enterprises,” per Santander’s website. To those clients, it’ll offer guidance on commercial strategy development, team building, revenue generation, business planning and development, and financial management. Santander has pledged to provide “hands-on support” in each of those areas, with an aim of “delivering tailored solutions that drive growth, maximize efficiency, and ensure compliance,” according to Michelle Yanez, the firm’s co-founder and chief financial officer. “At Santander Pharma Consulting, our mission is clear: to help our clients optimize their commercial success by leveraging our teams’ experience,” Robert Yanez, another co-founder and the firm’s CEO, added in the announcement. Fierce Pharma Marketing has reached out to Santander for clarification on the relation, if any, between Michelle Yanez and Robert Yanez. Each of the founders arrives at the consultancy with more than two decades of experience in the life sciences industry. Michelle spent the bulk of her career—from 2002 to 2022—at specialty pharma BioDelivery Sciences International, including a stint as director of financial reporting through BDSI’s acquisition by Collegium Pharmaceutical in early 2022. She joined Mira Pharmaceuticals as financial controller and director in May of that year and was named its CFO a year later. Robert, meanwhile, got his start as a product manager at GSK, Valeant Pharmaceuticals—now Bausch Health—and Johnson & Johnson. From there, he spent about six years in increasingly senior marketing director roles at XenoPort, followed by stints as director of commercial operations at BDSI and as senior director first of marketing and global research sales, then of strategic partnerships within the Americas, for devicemaker Circassia, now known as NIOX Group. Since early 2021, he’s served as chief commercial officer of Bryn Pharma.

DUBLIN, March 21, 2024 /PRNewswire/ -- The "Smart In-Vitro Diagnostics - Artificial Intelligence for In Vitro Diagnostics Markets by Application, by Technology and by User with Executive and Consultant Guides 2023-2027" report has been added to ResearchAndMarkets.com's offering. Will Smart Diagnostics replace the physician? Will the power of Artificial Intelligence provide better diagnostics? The market is moving out of a research mode into the clinic. The market is exploding as physicians use all the information they can get to battle disease. While Pharmaceutical Companies see the potential to make nearly any therapy viable. Find out how this new approach to diagnostics will change medical care forever. This report provides data that analysts and planners can use. Hundreds of pages of information including a complete list of United States Medicare Fee Payment Schedules to help understand the new pricing for nucleic acid based tests. Forecast demand for new testing regimes or technologies. Make research investment decisions. Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. Again, assistance in using the information is normally provided without additional charges. Learn all about how players are jockeying for position in a market that is being created from scratch. And some players are pulling way out in front and expanding globally. It is a dynamic market situation with enormous opportunity where the right diagnostic with the right support can command premium pricing. And the science is developing at the same time creating new opportunities with regularity. And the cost of many diagnostics continues to fall. Broad-spectrum blood testing and artificial intelligence will routinely provide medical diagnosis in the near future according to a this new report. The report looks at the current market situation and forecasts double digit growth. 'We have already seen how multiplex testing is displacing other test methods in infectious disease diagnostics. Adding artificial intelligence will lead to better and faster diagnosis for a much wider range of conditions' according to Greg Powell, President of the publisher. The report explores recent developments in artificial intelligence, genomics, and costs that affect the market outlook. 'A number of factors are all coming together at once that will change how medicine is practiced. In Vitro Diagnostics and Artificial Intelligence will be playing a much bigger role in the future.' said Mr Powell. 'Artificial intelligence is coming into use much faster than expected. The use in medical diagnosis is just starting in image analysis where AI is already helping Radiologists and Pathologists. We are expecting this trend to move into mainstream In Vitro Diagnostics more quickly than previously thought.' 'Several important trends in technology are driving down the costs of testing and providing more results from a single test. This has very broad implications for medical care and for the way that diagnosis is carried out. Artificial Intelligence will be changing this situation even more.' said Mr. Powell. Key Topics Covered: 1 Market Guides 1.1 Strategic Situation Analysis 1.2 Guide for Executives, Marketing, and Business Development Staff 1.3 Guide for Management Consultants and Investment Advisors 2 Introduction and Market Definition 2.1 What are Smart Diagnostics? 2.2 Market Definition 2.2.1 Revenue Market Size 2.3 Methodology 2.4 Perspective: Healthcare and the IVD Industry 2.4.1 Global Healthcare Spending 2.4.2 Spending on Diagnostics 2.4.3 Important Role of Insurance for Diagnostics 3 Market Overview 3.1 Players in a Dynamic Market 3.1.1 Academic Research Lab 3.1.2 Diagnostic Test Developer 3.1.3 Instrumentation Supplier 3.1.4 Chemical/Reagent Supplier 3.1.5 Pathology Supplier 3.1.6 Independent Clinical Laboratory 3.1.7 Public National/regional Laboratory 3.1.8 Hospital Laboratory 3.1.9 Physicians Office Lab (POLS) 3.1.10 Audit Body 3.1.11 Certification Body 3.2 Understanding Artificial Intelligence 3.2.1 Artificial intelligence 3.2.2 Machine learning 3.2.3 Deep learning 3.2.4 Convolutional neural networks 3.2.5 Generative adversarial networks 3.2.6 Limitations 3.3 AI Applications in IVD 3.3.1 Infectious Disease 3.3.1.1 Known vs. Unknown 3.3.1.2 TMI 3.3.1.3 Disease surveillance 3.3.1.4 Outbreak detection 3.3.1.5 Contact tracing 3.3.1.6 Forecasting 3.3.1.7 Drug discovery 3.3.1.8 Resource allocation 3.3.2 Oncology 3.3.2.1 Electronic health records 3.3.2.2 Genomic analysis 3.3.2.3 Treatment planning 3.3.2.4 Clinical trial matching 3.3.3 Anatomic Pathology 3.3.3.1 Image analysis 3.3.3.2 Tumor segmentation 3.3.3.3 Disease classification 3.3.3.4 Predictive modeling 3.3.3.5 Quality control 3.3.3.6 Digital pathology 3.3.4 Cardiology 3.3.4.1 Electrocardiogram analysis 3.3.4.2 Electronic health records 3.3.4.3 Genomic analysis 3.3.4.4 Treatment planning 3.3.4.5 Prediction of outcomes 3.3.5 Diabetes 3.3.5.1 Diagnosis 3.3.5.2 Blood glucose monitoring 3.3.5.3 Personalized treatment plans 3.3.5.4 Medication management 3.3.5.5 Diabetes education 3.3.5.6 Predictive analytics 3.3.6 General Medicine 3.3.6.1 Diagnosis 3.3.6.2 Predictive Analytics 3.3.6.3 Personalized Treatment Plans 3.3.6.4 Medication Management 3.3.6.5 Disease Monitoring 3.3.6.6 Telemedicine 4 Market Trends 4.1 Factors Driving Growth 4.1.1 Outcome Improvement 4.1.2 The Aging Effect 4.1.3 Cost Containment 4.1.4 Physician Impact 4.1.5 Cost of Intelligence 4.2 Factors Limiting Growth 4.2.1 State of knowledge 4.2.2 Genetic Blizzard 4.2.3 Protocol Resistance 4.2.4 Regulation and coverage 4.3 Instrumentation, Automation and Diagnostic Trends 4.3.1 Traditional Automation and Centralization 4.3.2 The New Automation, Decentralization and Point Of Care 4.3.3 Instruments Key to Market Share 4.3.4 Bioinformatics Plays a Role 4.3.5 PCR Takes Command 4.3.6 Next Generation Sequencing Fuels a Revolution 4.3.7 NGS Impact on Pricing 4.3.8 Whole Genome Sequencing, A Brave New World 4.3.9 Companion Diagnostics Blurs Diagnosis and Treatment 4.3.10 Shifting Role of Diagnostics 5 Recent Developments 5.1 Recent Developments - Importance and How to Use This Section 5.1.1 Importance of These Developments 5.1.2 How to Use This Section 5.2 Paige, Leica Biosystems Expand Digital Pathology Partnership 5.3 Clarapath Acquires Digital Pathology Company Crosscope 5.4 CanSense to Develop Colorectal Cancer Test 5.5 Owkin-led Machine Learning Study IDs Cancer Treatment Biomarkers 5.6 Guardant Health to Integrate Lunit's AI PD-L1 Algorithm 5.7 Vesale Bioscience to Develop AI Phage Therapy Diagnostic Platform 5.8 Caris Life Sciences To Use AI and Machine Learning 5.9 Numares Health To Develop AI for "Metabolite Constellations" 5.10 Sepsis Testing Startup DeepUll to Use AI for Medical Decisions 5.11 Viome Life Sciences Raises $67M in Series C Financing For AI Cancer Dx 5.12 ADM Diagnostics Wins Grant for Brain Injury Test Development 5.13 Paige to Develop New AI-based Pathology Test 5.14 Aiforia Gains CE-IVD Mark for AI-Powered Histopathology 5.15 Genetic Profiling May Identify Patients Who Do Not Need Radiation Therapy 5.16 Thermo Fisher Introduces Homologous Score for Cancer Profiling 5.17 Genomic Test IDs Cancer Cells Early 6 Profiles of Key Players 6.1 Adaptive Biotechnologies 6.2 Aidoc 6.3 Anumana 6.4 ARUP Laboratories 6.5 Atomwise 6.6 Bayesian Health 6.7 Behold.ai 6.8 BGI Genomics Co. Ltd 6.9 bioMerieux Diagnostics 6.10 Bio-Rad Laboratories, Inc 6.11 Cambridge Cognition 6.12 Cardiologs (Phillips) 6.13 CareDx 6.14 Caris Molecular Diagnostics 6.15 Cleerly 6.16 ClosedLoop AI 6.17 CloudMedX Health 6.18 Deepcell 6.19 Digital Diagnostics 6.20 EKF Diagnostics Holdings 6.21 Freenome 6.22 GE Healthcare 6.23 Glooko 6.24 Idoven 6.25 Illumina 6.26 Infohealth 6.27 Jade 6.28 K Health 6.29 Lunit 6.30 MaxCyte 6.31 Mayo Clinic Laboratories 6.32 Medtronic 6.33 Merative 6.34 Nanox 6.35 NIOX Group 6.36 Niramai Health Analytix 6.37 NVIDIA 6.38 Oncohost 6.39 OraLiva 6.40 Owkin 6.41 Oxford Nanopore Technologies 6.42 Pacific Biosciences 6.43 Paige.AI 6.44 PathAI 6.45 Perthera 6.46 Philips Healthcare 6.47 Prognos 6.48 Qiagen 6.49 Qure.ai 6.50 Renalytix 6.51 Seegene 6.52 Siemens Healthineers 6.53 Sophia Genetics 6.54 Sysmex 6.55 Viz.ai For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo - SOURCE Research and Markets